Drug Daraxonrasib Extends Survival in Pancreatic Cancer Trial

A drug that blocks the activity of a family of mutant proteins has extended survival for people with a deadly form of pancreatic cancer, according to a small clinical trial. The drug daraxonrasib shrank or halted the growth of pancreatic tumors in many of the participants.

The trial results were reported on 11 May 2026. Pancreatic cancer is known for being hard to treat and having low survival rates. The trial offers data on a potential new approach targeting mutant proteins that drive tumor growth.

The trial showed that patients receiving daraxonrasib survived longer than would typically be expected for this form of pancreatic cancer. Many participants experienced tumor shrinkage or stabilization. Nature reported that the drug targets specific mutations present in many pancreatic tumors.

Researchers observed the effects in a limited group of patients. Further studies will be needed to confirm the results in larger populations and compare the drug against existing treatments.

The company developing daraxonrasib has not announced timelines for larger trials or regulatory submissions. Pancreatic cancer affects thousands of patients each year in the United States with limited effective options available once the disease advances.

The trial adds to ongoing efforts to address mutations long considered difficult to target with medicines. Data from the study will be reviewed by other research teams working in the field.